Evidence review
Do You Regain Weight After Stopping a GLP-1? What the Trials Show
Compare GLP-1 withdrawal and maintenance trials, how much weight returned, and the care and cost questions to ask before changing treatment.
On this page
Weight regain is common after semaglutide or tirzepatide is withdrawn, but the amount varies. In the STEP 1 extension, the semaglutide group regained about two-thirds of its earlier loss over the following year. That was a group average after both medication and structured lifestyle support ended, not a forecast for every patient.3
The useful decision is how to plan for a change in treatment. Tell the prescriber why you are considering stopping, whether it is cost, side effects, access or your treatment goals. Changing companies is a separate decision: our provider-switching guide covers records, appointments and refill coordination.
What the withdrawal studies actually measured
The original STEP 1 and SURMOUNT-1 trials established weight loss during treatment with the studied medicines.1, 2 Withdrawal studies answer a different question: what happened after an initial treatment period ended or participants switched to placebo?
Scroll to compare all columns.
| Study | Follow-up after the initial treatment period | Main weight finding |
|---|---|---|
| STEP 1 extension | 52 weeks after 68 weeks of treatment; medication and structured lifestyle support ended | Semaglutide group regained 11.6 percentage points of original body weight, leaving a 5.6% loss from the original baseline.3 |
| STEP 4 | 48 weeks after randomization at week 20; lifestyle support continued | Weight rose 6.9% after switching to placebo and fell another 7.9% with continued semaglutide, measured from week 20.4 |
| SURMOUNT-4 | 52 weeks after randomization at week 36 | Weight rose 14.0% after switching to placebo and fell another 5.5% with continued tirzepatide, measured from week 36.5 |
The starting point matters. A change measured from the original baseline is different from a change measured after someone has already lost weight. These rows also describe different study populations and protocols; they are not a head-to-head comparison of which medicine causes less regain.
If your earlier treatment was bariatric surgery, our post-surgery evidence review separates poor initial loss from later recurrence.
Semaglutide: two studies with different limits
The STEP 1 extension included 327 participants across both original treatment groups. The semaglutide 2.4 mg injection group's earlier mean loss was 17.3%. Its subsequent regain is often summarized as "two-thirds," meaning two-thirds of the weight previously lost, not two-thirds of starting body weight. The extension was exploratory, and lifestyle support stopped alongside medication, so it cannot isolate the effect of withdrawing medication alone.3
STEP 4 provides a randomized withdrawal comparison. Of 902 people who entered the run-in, 803 reached the trial's 2.4 mg weekly maintenance-dose requirements and were randomized to continue semaglutide or switch to placebo. Both groups received lifestyle intervention. The results therefore describe people who reached that stage of treatment, rather than everyone who starts a prescription.4
Together, these studies make a strong case for discussing maintenance before a prescription ends. They do not show that every person will regain the same amount or establish an individual stopping schedule.
Tirzepatide: continued treatment and withdrawal diverged
SURMOUNT-4 enrolled 783 adults without diabetes in its initial treatment period; 670 were randomized after 36 weeks. At 10 or 15 mg weekly, their mean loss before randomization was 20.9%. After another year, 89.5% of those continuing tirzepatide had maintained at least 80% of that earlier loss, compared with 16.6% after switching to placebo.5
That supports a benefit from continued treatment in the population studied. It does not tell a patient exactly how quickly weight would return after stopping, or prove the result for a different formulation. A trial of a specified medicine is not evidence that every compounded preparation or provider produces the same outcome.
Can a different medicine support maintenance?
Switching medication is different from stopping medication. The 2026 ATTAIN-MAINTAIN trial randomized people previously treated with tirzepatide or semaglutide in SURMOUNT-5 to daily oral orforglipron or placebo. The two cohorts included 205 and 171 participants, respectively. Among participants who had reached a weight plateau, the orforglipron groups maintained more of their earlier loss at 52 weeks.9
There was no group continuing the injectable medicine, and follow-up lasted one year. The study therefore supports a maintenance option to discuss with a prescriber; it does not establish that switching is equivalent to staying on an injection. Our Wegovy tablets versus Foundayo guide explains why "a GLP-1 pill" is not a sufficient product description.
Dose reduction is another distinct question. SURMOUNT-MAINTAIN studied continued tirzepatide at 10 or 15 mg, a reduction to 5 mg, or placebo after a 60-week initial treatment period, followed for another 52 weeks.10 Those are study arms, not a tapering schedule to copy. Ask the prescriber which evidence applies to the proposed change and what monitoring it requires.
Why appetite and other health goals belong in the conversation
A small study of 50 adults entering a very-low-energy diet program found that changes in appetite-related hormones and hunger persisted a year after initial weight loss. This was a diet study, not a GLP-1 withdrawal trial.7 It helps explain why maintaining a loss can remain difficult; it cannot predict one person's response after a medication change.
Continued-treatment studies also have limits. STEP 5 found sustained weight loss over 104 weeks with semaglutide versus placebo, but two years of follow-up is not evidence for an identical lifetime plan for everyone.6
Some people take these medicines for health goals beyond the scale. SELECT found fewer major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight or obesity, without diabetes. It was not a randomized withdrawal study and does not quantify what happens to an individual's cardiovascular risk after stopping.8 Our guide to benefits beyond weight loss separates the studied conditions and populations.
What to ask before changing treatment
Take a short set of questions to the prescriber:
- What is the reason for continuing, changing or stopping this particular treatment?
- Which changes in weight, symptoms or other health measures should prompt a follow-up, and when is that appointment?
- If cost or coverage is the problem, what alternatives fit my prescription and circumstances?
- If there is a gap in care, who provides advice before the next dose? Our missed-dose and restart guide explains why an old prescription does not settle a restart decision.
Keep the clinical plan separate from the payment agreement. Stopping a medicine does not confirm that a subscription has ended, and canceling renewal does not necessarily refund a prepaid purchase. Our cancellation guide sets out those separate requests.
Compare providers for the care you expect to use
A low starting price tells you little about an ongoing treatment budget. Ask for the continuing medication price, the supply period, appointment and lab charges, renewal terms and the route to follow-up care. Our six-month cost guide helps organize those figures without turning an unresolved quote into a total.
For example, the Omada Health review distinguishes benefit-sponsored support from medication access and payment. The Rx.com review examines monthly versus prepaid purchasing and what remains unclear about an unused balance. Those are different arrangements to investigate, not evidence that either service prevents regain.
Our methodology scores cost value, dose and formulation, clinical oversight, labs and monitoring, fulfillment, and contract terms. Ongoing care cuts across these subjects; a provider's score is not a prediction of weight change.
Our recommendation is to settle the follow-up and continuing bill before committing to a longer purchase. Use the trial evidence to frame that conversation, then choose care around the clinician's plan rather than assuming an introductory offer is a complete maintenance program.
Frequently asked questions
How much weight comes back after stopping semaglutide?
The STEP 1 extension found that the semaglutide group regained about two-thirds of its earlier loss in a year. That was an average after medication and lifestyle support ended, not an individual forecast.
What happened after tirzepatide was stopped in SURMOUNT-4?
After switching to placebo, average weight rose 14.0% over 52 weeks, measured from the lower weight at randomization. This is different from 14.0% of original starting weight.
Does the research mean everyone needs lifelong treatment?
The studies support a conversation about ongoing treatment, but they do not establish an identical lifetime prescription for everyone. A clinician should weigh the treatment goals, response, adverse effects and alternatives.
Can I taper a GLP-1 to prevent regain?
A dose-reduction study is not a tapering schedule for individual use. Ask your prescriber which evidence applies to a proposed change and how follow-up will work.
Will canceling my subscription also end every medication charge?
Check the membership and prescription-order terms separately. Canceling renewal does not necessarily stop a pending pharmacy order or return an unused prepaid balance.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. New England Journal of Medicine. PubMed · PMID 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PubMed · PMID 35658024
- Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, Obesity and Metabolism. PubMed · PMID 35441470
- Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. PubMed · PMID 33755728
- Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA. PubMed · PMID 38078870
- Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.. Nature Medicine. PubMed · PMID 36216945
- Sumithran P, Prendergast LA, Delbridge E, et al. (2011). Long-term persistence of hormonal adaptations to weight loss.. New England Journal of Medicine. PubMed · PMID 22029981
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.. New England Journal of Medicine. PubMed · PMID 37952131
- Aronne LJ, Horn DB, le Roux CW, et al. (2026). Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.. Nature medicine. PubMed · PMID 42120723
- Horn DB, Aronne LJ, Wharton S, et al. (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.. Lancet (London, England). PubMed · PMID 42119587
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
EverPrime Review: Membership, Total Costs and the Exit Terms
EverPrime pairs GLP-1 treatment with optional membership. Compare combined prices, upfront commitments, cancellation deadlines and pharmacy questions.
ReadFOLX Health Review: GLP-1 Visits, Membership and Medication Costs
FOLX offers GLP-1 prescribing through metabolic care. Compare its membership, visit and pharmacy charges before budgeting for treatment.
ReadGLP-1s After Bariatric Surgery: What Was Studied
Compare postoperative trials by surgery, weight history and follow-up, without treating study averages as a personal treatment plan.
ReadGLP-1 Payment Plans: A Smaller Installment Can Hide a Larger Commitment
Compare the cash total, financed balance, interest terms and refund process before using a payment plan for GLP-1 treatment.
ReadLiraglutide vs. Semaglutide: Daily or Weekly?
Compare daily liraglutide with weekly semaglutide injections: STEP 8 results, treatment burden, product differences and the questions behind a price quote.
ReadMissed a GLP-1 Dose? Separate a Late Injection From a Treatment Restart
Compare Wegovy injection and Zepbound missed-dose instructions, understand longer interruptions, and prepare the questions your prescriber needs to answer.
Read